Monthly research recap
Serotonin research: September 2026
What September 2026's 18 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 18 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research indexed in September 2026 on serotonin was dominated by mechanistic and preclinical work rather than new clinical trials. Across receptor-level, animal, and computational studies, the 5-HT2A receptor remained central to psychedelic action, but several studies reported that key therapeutic-like effects (fear extinction, neuroplasticity, antidepressant-like behavior) can involve or even bypass 5-HT2A, implicating 5-HT1A, 5-HT1B, and 5-HT2B. The evidence is largely from rodent and in silico models with small samples and short follow-up, so clinical translation and durability remain unestablished.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Moving beyond 5-HT2A: language models map neurotransmitter receptors to experiential semantics. 2026 | computational proof-of-concept study | 4496 | Supports | A semantic embedding model combined with receptor binding data linked 5-HT2A to classic psychedelic experience and identified novel associations of 5-HT1A/5-HT1B with cognitive disruption, H1 with interdimensional communication, and 5-HT7a/5-HT1E with visual complexity. |
| Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure 2026 | theoretical or philosophical paper | Unclear | Argues that dosing schedule should be an independent pharmacological variable in psilocybin microdosing research, noting that the first dedicated randomized trial in major depressive disorder (2 mg once weekly) did not show superiority over placebo and that continuous exposure remains inadequately tested. | |
| Deciphering the allosteric landscape of 5-HT2 receptors: integrated molecular dynamics and fragment molecular orbital analyses of activation mechanisms 2026 | computational modeling study | Supports | Reports that 5-HT2 receptor signaling operates through a cooperative allosteric network with R3.50 as a mandatory endpoint, that 5-HT2B has the most pre-organized network, 5-HT2A is most perturbation-sensitive, and residues D3.32, S5.46, and W6.48 are critical energetic determinants of ligand efficacy. | |
| Exploring a Druggable Hydrophobic Tunnel in the 5-HT2A Receptor with Potent Phenethylamines 2026 | theoretical and experimental molecular pharmacology study | Supports | Reports that a hydrophobic tunnel lateral to the 5-HT2A orthosteric site, involving Gly2385x43, accommodates C-4 phenyl-ring substituents of at least four heavy atoms, and that such phenethylamine analogs show agonist potency, identifying the tunnel as a druggable region. | |
| The serotonin 1B receptor as a target for the treatment of depression and anxiety 2026 | review | Supports | Argues that 5-HT1B receptors are a tractable therapeutic target for mood disorders, citing preclinical evidence that 5-HT1B agonists and p11-dependent trafficking produce antidepressant-like effects and that 5-HT1B signaling is required for psilocybin's sustained pro-hedonic and anxiolytic actions. | |
| Single ayahuasca administration mitigates long-term behavioral and neurochemical effects of early-life stress in rats. 2026 | preclinical animal study (experimental) | Supports | A single dose of ayahuasca attenuated maternal-deprivation-induced anxiety- and depressive-like behaviors and neurochemical changes (BDNF, monoamines, oxidative stress) when assessed 15 days later. | |
| Serotonergic psychedelics and amphetamine shift male rat ultrasonic vocalizations toward call patterns associated with positively valenced states. 2026 | observational study | Mixed | DOI and LSD induced head-twitch responses while only amphetamine increased activity; total ultrasonic vocalizations increased after amphetamine and both DOI doses, but cluster analyses indicated compounds altered the vocal repertoire rather than simply increasing overall calling. | |
| Mechanistic Basis for 5-HT2AR Over 5-HT2BR Activation 2026 | theoretical or philosophical paper | Supports | Reports that steric and conformational constraints in the side-extended and extended binding pockets of 5-HT2AR and 5-HT2BR determine ligand orientation and signaling, and that designed derivatives and cryo-EM structures with IHCH-2330 confirm a strategy for selective 5-HT2AR activation while limiting 5-HT2BR activity. | |
| 5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice. 2026 | controlled preclinical experiment in rodents | Opposes | Psilocybin facilitated fear extinction and increased BDNF and doublecortin-positive neurons even when 5-HT2A was blocked by ketanserin or MDL100907, indicating these effects are not dependent on 5-HT2A receptor activation. | |
| 5-HT2A receptor and psychedelics: a trip through the mechanisms of action and therapeutic potential in mental disorders 2026 | review | Supports | Argues that psychedelics act as 5-HT2A receptor agonists producing alterations in cognition, perception, and mood hypothesized to stem from circuit-specific modulation of neurotransmission and neuroplasticity, while noting that the precise neural circuits linking 5-HT2AR activation to behavioral outcomes remain unmapped. | |
| Modulating the Thermodynamics and Kinetics of Psychedelics at Serotonin Receptors via Terahertz Waves 2026 | in vitro experimental study integrating molecular dynamics simulations | Supports | Specific terahertz frequencies (42.4 and 48.6 THz) enhanced LSD and psilocin binding to 5-HT1AR and 5-HT2AR in simulations and potentiated their downstream Gi and Gq signaling in vitro, generally prolonging predicted ligand residence times except for LSD at 5-HT1AR at 48.6 THz. | |
| 805. Rapid Antidepressant-Like Effects of 5-MeO-DMT Require Both 5-HT 1A and 5-HT 2A Receptors 2026 | randomized controlled trial | Supports | 5-MeO-DMT (10 mg/kg) produced rapid antidepressant-like effects in the forced swim test that were blocked by both 5-HT1A and 5-HT2A antagonism but not by 5-HT7 or sigma antagonists, and head-twitch responses could be dissociated from antidepressant-like efficacy. | |
| Psilocybin selectively suppresses novelty-induced grooming via 5-HT2B receptors: A microstructure analysis in Wistar rats. 2026 | observational study | Supports | Psilocybin reduced novelty-induced grooming mainly by selectively suppressing abnormal, non-comfort grooming microstructure, and RS-127445 reversed the reduction in total grooming time and bouts and blocked suppression of fragmented bout and aberrant transition patterns, implicating 5-HT2B receptors. | |
| 650. Anxiolytic effects of serotoninergic psychedelics on patients with psychiatric disorders 2026 | systematic review and meta-analysis | 9 | Unclear | Only 9 studies met inclusion criteria and data extraction and analysis were still being finalized; the authors conclude that data on effectiveness and safety of serotonergic psychedelics for anxiety symptoms are scarce and that more research is needed. |
| Deconstruction of lysergic acid diethylamide. 2026 | laboratory study | Mixed | Systematic deconstruction of the LSD ergoline core yielded 9 simplified analogues, identified the minimal pharmacophore for maximal 5-HT2A agonism and hallucinogenic behavior, and identified UCD0076 as a 5-HT2C-preferring ergolog with antipsychotic-like properties in mice. | |
| Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis 2026 | theoretical or philosophical paper | Unclear | Proposes that daily low-dose psilocybin may induce progressive 5-HT2A receptor desensitization, with fading subjective effects marking an adaptive state rather than therapeutic failure, and that intermittent schedules may test different chronic pharmacology; the hypothesis arose from one uncontrolled personal observation and is not evidence of efficacy. | |
| 469. The serotonin 5-HT2A agonist psilocybin in the treatment of neuropathic pain 2026 | preclinical animal study | Mixed | Psilocybin did not significantly reverse mechanical allodynia over five hours or alter ON/OFF cell firing in the rostral ventromedial medulla, but significantly reduced elevated firing of glutamatergic neurons in the anterior cingulate cortex of neuropathic rats. | |
| Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress. 2026 | preclinical animal study | Supports | Psilocin administered after chronic social defeat stress ameliorated social avoidance behavior, while administration before stress had little effect, and the therapeutic effect was blocked by a 5-HT2A receptor antagonist. |
Points of agreement
- 5-HT2A receptor activation remains the principal framework for explaining psychedelic subjective and behavioral effects.
- Several therapeutic-like outcomes in animal models (fear extinction, neuroplasticity, antidepressant-like behavior) involve serotonergic receptors beyond 5-HT2A, including 5-HT1A, 5-HT1B, and 5-HT2B.
- Receptor-level structural and computational work consistently describes 5-HT2 receptor signaling as a cooperative, multi-residue allosteric process rather than a simple on/off switch.
- Multiple studies report that hallucinogenic and therapeutic effects can be dissociated, supporting interest in non-hallucinogenic or functionally selective compounds.
Conflicts
- One rodent study reports psilocybin's fear extinction and neuroplasticity effects persist with 5-HT2A blockade, while another reports psilocin's social-avoidance benefit is blocked by a 5-HT2A antagonist.
- 5-MeO-DMT's antidepressant-like effects required both 5-HT1A and 5-HT2A, whereas psilocybin's fear-extinction effects were reported as 5-HT2A-independent.
- Psilocybin showed no significant anti-allodynia in a neuropathic pain model despite modulating cortical excitatory neuron firing, leaving its analgesic relevance unclear.
Gaps
- Most evidence is preclinical (rodent, in vitro, or computational); human clinical data on serotonin-targeted psychedelics remain sparse.
- Durability of effects is largely untested beyond short follow-up windows (e.g., 15 days in one animal study).
- Dosing schedule (daily vs intermittent) and its relationship to 5-HT2A adaptation are hypothesized but not empirically compared.
- Blinding, expectancy, and placebo control are not addressed in the animal and computational work.
- Sex- and stress-dependent effects of 5-HT1B and other receptor targets are proposed but not established.
- Long-term safety, including possible 5-HT2B-mediated valvulopathy, is unresolved.